Voronoi said Monday that the company would step up its open innovation business by developing new drugs based on AI.

Market watchers interpreted it as a strategy to discover candidates for other companies by utilizing AI drug development platforms and generating profits.

"Through technology transfer and successive clinical verification schedules, awareness of Voronoi has increased overseas," a company official said. "Recently, we had open innovation discussions in the U.S. and other countries and are officially announcing an open innovation plan for AI drug development."‧

Voronoi added that it has applied for a patent for AI technology related to lead optimization of pipeline candidates.

"By utilizing Voronoi's AI platform, collaborators can quickly identify candidates with high selectivity and BBB (brain blood barrier) permeability," said Kim Hyun-tae, CEO of Voronoi’s management division. "Voronoi has the advantage of securing pipeline stakes through open innovation to increase profitability and expand research areas."

Voronoi is also looking forward to presenting the results of its technology transfer partner ORIC Pharmaceuticals’ phase 1 clinical trial of ORIC-114 for non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology (ESMO) in October.